Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group LSE:RENE London Ordinary Share GB00B0DZML60 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025p -1.27% 1.95p 1.90p 2.00p - - - 0 07:35:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -18.2 -0.5 - 61.71

Reneuron Share Discussion Threads

Showing 5501 to 5523 of 5525 messages
Chat Pages: 221  220  219  218  217  216  215  214  213  212  211  210  Older
DateSubjectAuthorDiscuss
13/11/2017
09:10
In the old eyeball ?
dogwalker
13/11/2017
08:56
Steady pressure is encouraging.
small crow
09/11/2017
12:29
The obvious next step would be to look for action in patients that suffered from glaucoma or macular degeneration.
masingi
09/11/2017
10:31
Small Crow- It is the most prevalent form of inherited blindness and affects 1/4000 people within their lifetime, on average.
masingi
08/11/2017
07:16
Encouraging news. Anyone have potential market sizes for these two conditions to hand?
small crow
07/11/2017
10:23
nsk1 - Yes and it has been going on for some time without a peep from the company. They know who it is and why but no comments - Not Good!
deutsch3
07/11/2017
09:13
Somebody is dumping shares yet again
nsk1
06/11/2017
18:59
There seems to be a bit more upwards pressure. A nice steady rise to 20p would be nice. Lol
yachtmaster2
03/11/2017
05:26
I would assume RENE will submit an application when they are able to http://www.bbc.co.uk/news/health-41843320
stevedd
01/11/2017
18:58
masingi Sound advice, I'll have to try it.
ps0u3165
01/11/2017
14:53
My favourite long-term trend is the one of income from US oil companies just before the first gusher in Pennsylvania. Trend wasn't much of a friend in that one! For more details, read "The Prize".
small crow
01/11/2017
14:41
For this kind of company, long term trends aren't relevant... Just news items and exposure. D
dennisbergkamp
01/11/2017
14:19
ps0u3165: "I can see the wood, however most of the trees have been burn't. Look at the LT chart and tell me which way its trending. IMHO it will not change significantly for a long time to come." ...unless there is a buy-out, a marketing deal, a US stock listing, or the market starts to price-in future potential as results come through. All of which is driven by rumour and news. Rumour and news cannot be predicted by LT trends. Not much can, to be honest. All I can suggest is buy into the falls and sell into the rises (not the other way round).
masingi
01/11/2017
14:08
I can see the wood, however most of the trees have been burn't. Look at the LT chart and tell me which way its trending. IMHO it will not change significantly for a long time to come.
ps0u3165
01/11/2017
12:54
I added another chunk yesterday. Clinical development programs take years so we have some way to go. Trial design will be influenced by statistical robustness not cost. If they need more money, the impact will be minimal compared to the potential upside. My main concerns about the ability of that potential to be realised are: 1) will the treatment work? All the indications to date are that it does 2) is it cost effective such that agencies will approve it for use....NHS won't pay if it's too expensive! 3) is there any competition that can beat them to market. I don't know for sure but my understanding is that they are the front runners If further trials reinforce the effectiveness they there's a high chance that regulatory approvals will be expedited. I've no clue as to the potential upside in share price but it has to be many multiples of where we are today. For me, the risks are worth the potential upside and the risk is that they fail to deliver an effective product and I loose all of my investment.
audigger
01/11/2017
12:00
I somehow suspect he doesn't want to see the wood....
small crow
01/11/2017
11:11
Only one more study before market. Says it quite clearly, you just need to see the wood for the trees
bigspuds
01/11/2017
11:02
I predict a TO before any more cash calls. There's boldness for you.
small crow
01/11/2017
10:39
Patience been waiting over 10 yrs to-date. Last cash call was at 3p, next 1p? Edit
ps0u3165
01/11/2017
09:54
Of course they will need funds; with a world changing treatment for stroke these should be easy to come by.
bonzo
01/11/2017
09:53
Patience always needed!
small crow
01/11/2017
09:50
So we could be talking years not months. If so the cash will be gone, they may have cut the sample size to keep the cash burn down. However its unlikely to see any product through to market so more cash calls will be needed.
ps0u3165
01/11/2017
09:37
As a takeover target this seems amazingly tempting. Cash in the bank and loads of potential. I know big pharma doesn't take risks but, given the cash situation, the potential is pretty well free.
small crow
Chat Pages: 221  220  219  218  217  216  215  214  213  212  211  210  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171120 07:56:05